Dexmedetomidine Combined With Lidocaine Infusion Affect Inflammation Cytokines

NACompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

November 1, 2017

Primary Completion Date

August 6, 2020

Study Completion Date

August 10, 2020

Conditions
Anesthesia; Reaction
Interventions
DRUG

Saline

Participants in the group CON were received normal saline infusion until 30 min before the end of the operation.Interleukin-6 and tumor necrosis factor-α levels in serum were measured at different time points: before administration of drugs (T1), at the end of the operation (T2), postoperative 2 hour (T3) and postoperative 24 hour (T4)

DRUG

Lidocaine

Participants in the group LIDO received lidocaine infusion (1.5 mg/kg loading, 1.5 mg/kg/h infusion)until 30 min before the end of the operation.Interleukin-6 and tumor necrosis factor-α levels in serum were measured at different time points: before administration of drugs (T1), at the end of the operation (T2), postoperative 2 hour (T3) and postoperative 24 hour (T4)

DRUG

Dexmedetomidine

Participants in the group DEX received dexmedetomidine infusion (0.5 µg/kg loading, 0.4 µg/kg/h infusion) until 30 min before the end of the operation. Interleukin-6 and tumor necrosis factor-α levels in serum were measured at different time points: before administration of drugs (T1), at the end of the operation (T2), postoperative 2 hour (T3) and postoperative 24 hour (T4)

DRUG

Lidocaine plus Dexmedetomidine

Participants in the group LIDO+DEX were received lidocaine (1.5 mg/kg loading, 1.5 mg/kg/h infusion) and dexmedetomidine infusion (0.5 μg/kg loading, 0.4 μg/kg/h infusion) until 30 min before the end of the operation, respectively. Interleukin-6 and tumor necrosis factor-α levels in serum were measured at different time points: before administration of drugs (T1), at the end of the operation (T2), postoperative 2 hour (T3) and postoperative 24 hour (T4)

Trial Locations (1)

246000

Department of Anqing Hospital Anesthesiology, Anqing

All Listed Sponsors
collaborator

The First Affiliated Hospital of Anhui Medical University

OTHER

lead

Anqing Municipal Hospital

OTHER

NCT03276533 - Dexmedetomidine Combined With Lidocaine Infusion Affect Inflammation Cytokines | Biotech Hunter | Biotech Hunter